From a release form the Company earlier in the year. I wonder if they have the approval considering we are into the second month of Q3 2022 come tomorrow???
Obtaining FDA clearance for additional AI algorithms under StrokeViewer is in process. These algorithms - pinpointing occlusions and measuring alternative blood supplies to the brain - give a significant competitive advantage in the US market. We are nearing the end of our clinical evaluation study, and the outcome of our FDA application is expected towards the end of Q2 2022.
